Gill J, Shah T, Hristea I, Chavalitdhamrong D, Anastasi B, Takemoto S K, Bunnapradist S
UCLA Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Am J Transplant. 2009 Apr;9(4):844-52. doi: 10.1111/j.1600-6143.2009.02588.x.
Simultaneous heart-kidney transplantation (SHK) remains uncommon in the US. We examined outcomes of SHK compared to heart transplant alone (HTA) and deceased donor kidney transplant (DDKT). Data from OPTN/UNOS heart and kidney data bases were used to identify 16,710 HTA, 263 SHK transplants and 68,833 DDK transplants between 1998 and 2007. Outcomes included patient survival (PS), acute cardiac and renal rejection and renal graft survival (rGS). The adjusted risk of death was 44% lower with SHK compared to HTA. Over half of SHK were performed in cases where pretransplant dialysis was not initiated. In these cases, there was no significant difference in the risk of death between SHK and HTA (HR 1.01; 95% CI 0.67-1.50). Recipients of SHK had worse 1-year rGS and PS and had a higher relative risk of overall renal graft loss compared to DDKT recipients. One-year rates of cardiac (14.5%) and renal (6.5%) rejection were lower in SHK compared to HTA and DDKT, respectively. Recipients of SHK had a lower adjusted risk of death compared to HTA recipients, particularly in patients who required pretransplant dialysis. These data suggest that SHK should be considered in heart transplant candidates with renal failure requiring dialysis, whereas the utility of SHK in cases of renal failure not requiring dialysis warrants further study.
在美国,心脏-肾脏联合移植(SHK)仍然并不常见。我们比较了心脏-肾脏联合移植与单纯心脏移植(HTA)以及尸体供肾移植(DDKT)的结果。利用器官获取与移植网络(OPTN)/美国器官共享联合网络(UNOS)的心脏和肾脏数据库的数据,来确定1998年至2007年间的16710例单纯心脏移植、263例心脏-肾脏联合移植以及68833例尸体供肾移植。结果包括患者生存率(PS)、急性心脏和肾脏排斥反应以及肾移植存活率(rGS)。与单纯心脏移植相比,心脏-肾脏联合移植调整后的死亡风险降低了44%。超过半数的心脏-肾脏联合移植是在移植前未开始透析的情况下进行的。在这些病例中,心脏-肾脏联合移植与单纯心脏移植的死亡风险没有显著差异(风险比1.01;95%置信区间0.67 - 1.50)。与尸体供肾移植受者相比,心脏-肾脏联合移植受者的1年肾移植存活率和患者生存率更差,总体肾移植丢失的相对风险更高。与单纯心脏移植和尸体供肾移植相比,心脏-肾脏联合移植的1年心脏排斥率(14.5%)和肾脏排斥率(6.5%)分别更低。与单纯心脏移植受者相比,心脏-肾脏联合移植受者调整后的死亡风险更低,尤其是在需要移植前透析的患者中。这些数据表明,对于需要透析的肾衰竭心脏移植候选者应考虑进行心脏-肾脏联合移植,而对于不需要透析的肾衰竭病例,心脏-肾脏联合移植的效用值得进一步研究。